Literature DB >> 33558076

Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart.

Ting Li1, Hui Liu1, Hongling Yu1, Jingtao Qiao1, Lisi Sun1, Yerong Yu2.   

Abstract

PURPOSE: The present study compared the interindividual variability in the pharmacodynamic (PD) and pharmacokinetic (PK) properties of a short-acting recombinant human insulin to those of insulin aspart through manual euglycemic glucose clamp tests.
METHODS: Sixty healthy Chinese male volunteers were randomly assigned to receive human insulin or insulin aspart, administered via SC injection (0.2 U/kg). For the evaluation of interindividual variability in PD and PK properties (glucose infusion rate [GIR], insulin concentration [INS]) through euglycemic clamp studies, %CVs were calculated, and PK/PD interindividual variability was compared between the 2 groups.
FINDINGS: The differences between the human insulin and insulin aspart groups in interindividual variabilities in total AUCs of the GIR (19% vs 21%) and INS (14% vs 17%) were not significant. The interindividual variabilities in AUCgir0-120min, early Tmax50%, and AUCins0-120min were lower in the insulin aspart group than in the human insulin group (22% vs 44%, 21% vs 35%, and 22% vs 28%, respectively; all, P ˂ 0.05), while the interindividual variabilities in the AUCs of GIR120-600min and INS120-600min were higher with insulin aspart than with human insulin (29% vs 20%, 51% vs 30%; both, P ˂ 0.05). IMPLICATIONS: The overall interindividual variability with insulin aspart was similar to that with recombinant human insulin. Yet insulin concentration and metabolic effect during the declining period were more variable with insulin aspart compared to human insulin in these healthy male subjects.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  euglycemic glucose clamp; insulin aspart; pharmacodynamics; pharmacokinetics; recombinant human insulin; variability

Year:  2021        PMID: 33558076     DOI: 10.1016/j.clinthera.2021.01.008

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  3 in total

1.  Effects of Glimepiride Combined with Recombinant Human Insulin Injection on Serum IGF-1, VEGF and TRACP-5b Oxidative Stress Levels in Patients with Type 2 Diabetes Mellitus.

Authors:  Xue Chen; Sheng Kang; Zeqing Bao
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-06       Impact factor: 2.650

2.  Commentary: Reduction in C-Peptide Levels and Influence on Pharmacokinetics and Pharmacodynamics of Insulin Preparations: How to Conduct a High-Quality Euglycemic Clamp Study.

Authors:  Hui Liu; Hongling Yu; Ting Li; Yerong Yu
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

3.  How to Achieve Sufficient Endogenous Insulin Suppression in Euglycemic Clamps Assessing the Pharmacokinetics and Pharmacodynamics of Long-Acting Insulin Preparations Employing Healthy Volunteers.

Authors:  Hui Liu; Ting Li; Hongling Yu; Jiaqi Li; Huiwen Tan; Yerong Yu
Journal:  Front Pharmacol       Date:  2022-07-22       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.